In western Europe, sales of anesthetics generated revenues of some $1.59billion in 1996, and this market is forecast to reach a level of $201 billion by the year 2003, according to marketing consultants Frost & Sullivan.
The largest product segment of the total anesthetics market is intravenous products, accounting for a 38.2% share in 1996. Local anesthetics represent the second largest sector in terms of revenues, valued at 27.5%, followed by the inhalation market, taking 22.0%. Germany is the largest market, accounting for 28.0% of 1996 revenues, while the UK takes 22.9%.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze